Anastrozole (‘Arimidex’) versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: Results of the double-blind cross-over SAKK trial 21/95 - a sub-study of the TARGET (Tamoxifen or ‘Arimidex’ Randomized Group Efficacy and Tolerability) trial
Titel:
Anastrozole (‘Arimidex’) versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: Results of the double-blind cross-over SAKK trial 21/95 - a sub-study of the TARGET (Tamoxifen or ‘Arimidex’ Randomized Group Efficacy and Tolerability) trial
Auteur:
Thürlimann, Beat Hess, Dagmar Köberle, Dieter Senn, Isabella Ballabeni, Pierluigi Pagani, Olivia Perey, Lucien Aebi, Stefan Rochlitz, Christoph Goldhirsch, Aron